Home Other Building Blocks DEACETYLNORGESTIMATE (25 MG) ((E)- AND (Z)-17-DEACETYL NORGESTIMATE MIXTURE)

DEACETYLNORGESTIMATE (25 MG) ((E)- AND (Z)-17-DEACETYL NORGESTIMATE MIXTURE)

CAS No.:
53016-31-2
Catalog Number:
AG00DANW
Molecular Formula:
C21H29NO2
Molecular Weight:
327.4605
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
5mg
99%
1 week
United States
$223
- +
10mg
99%
1 week
United States
$290
- +
50mg
99%
1 week
United States
$1057
- +
Product Description
Catalog Number:
AG00DANW
Chemical Name:
DEACETYLNORGESTIMATE (25 MG) ((E)- AND (Z)-17-DEACETYL NORGESTIMATE MIXTURE)
CAS Number:
53016-31-2
Molecular Formula:
C21H29NO2
Molecular Weight:
327.4605
MDL Number:
MFCD03695603
IUPAC Name:
(8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-3-hydroxyimino-1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-17-ol
InChI:
InChI=1S/C21H29NO2/c1-3-20-11-9-17-16-8-6-15(22-24)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,13,16-19,23-24H,3,5-12H2,1H3/t16-,17+,18+,19-,20-,21-/m0/s1
InChI Key:
ISHXLNHNDMZNMC-XUDSTZEESA-N
SMILES:
O/N=C/1\CC[C@H]2C(=C1)CC[C@@H]1[C@@H]2CC[C@]2([C@H]1CC[C@@]2(O)C#C)CC
UNII:
R0TAY3X631
Properties
Complexity:
642  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
6  
Defined Bond Stereocenter Count:
0
Exact Mass:
327.22g/mol
Formal Charge:
0
Heavy Atom Count:
24  
Hydrogen Bond Acceptor Count:
3  
Hydrogen Bond Donor Count:
2  
Isotope Atom Count:
0
Molecular Weight:
327.468g/mol
Monoisotopic Mass:
327.22g/mol
Rotatable Bond Count:
2  
Topological Polar Surface Area:
52.8A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
1  
XLogP3:
3.6  
Literature
Title Journal
Differences in prescription rates and odds ratios of antidepressant drugs in relation to individual hormonal contraceptives: a nationwide population-based study with age-specific analyses. The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception 20120401
Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188. Journal of acquired immune deficiency syndromes (1999) 20101201
Effects of the contraceptive patch and the vaginal ring on bone metabolism and bone mineral density: a prospective, controlled, randomized study. Contraception 20100301
Determination of norelgestromin in rabbit plasma by LC-MS/MS and its application to the pharmacokinetic study of ORTHO EVRA. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20090115
Influence of taranabant, an orally active, highly selective, potent cannabinoid-1 receptor (CB1R) inverse agonist, on ethinyl estradiol and norelgestromin plasma pharmacokinetics. Journal of clinical pharmacology 20090101
Satisfaction and compliance in hormonal contraception: the result of a multicentre clinical study on women's experience with the ethinylestradiol/norelgestromin contraceptive patch in Italy. BMC women's health 20090101
Effects of oral and transdermal hormonal contraception on vascular risk markers: a randomized controlled trial. Obstetrics and gynecology 20080201
A clinical study of transdermal contraceptive patch in Thai adolescence women. Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20080201
Effect of the ethinylestradiol/norelgestromin contraceptive patch on body composition. Results of bioelectrical impedance analysis in a population of Italian women. Nutrition journal 20080101
Oral and transdermal hormonal contraception in women after kidney transplantation. Transplantation proceedings 20071101
Pharmacokinetics and pharmacodynamics of a transdermal contraceptive patch and an oral contraceptive. Journal of clinical pharmacology 20070401
Antiandrogenic activity of norgestimate in a human androgen-dependent stable-transfected cell line. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 20070401
Performance of contraceptive patch compared with oral contraceptive pill in a high-risk population. Obstetrics and gynecology 20061201
A clinical study of transdermal contraceptive patch in Thai women. Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20061001
The Evra (ethinyl estradiol/norelgestromin) contraceptive patch: estrogen exposure concerns. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 20060117
How should we advise patients about the contraceptive patch, given the FDA warning? Cleveland Clinic journal of medicine 20060101
New warning on birth control patch. FDA consumer 20060101
Hormonal contraception: recent advances. The journal of family health care 20060101
[Safety evaluation of a transdermal contraceptive system with an oral contraceptive]. Ginekologia polska 20051101
Norelgestromin/ethinyl estradiol transdermal system. Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20051001
Extended use of transdermal norelgestromin/ethinyl estradiol: a randomized trial. Obstetrics and gynecology 20050601
Suppression of estrogen-withdrawal headache with extended transdermal contraception. Fertility and sterility 20050601
Effect of oral versus transdermal steroidal contraceptives on androgenic markers. American journal of obstetrics and gynecology 20050601
Adolescents' experience with the combined estrogen and progestin transdermal contraceptive method Ortho Evra. Journal of pediatric and adolescent gynecology 20050401
Preference for and satisfaction of Canadian women with the transdermal contraceptive patch versus previous contraceptive method: an open-label, multicentre study. Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC 20050401
Effect of multiple-dose dexloxiglumide on the pharmacokinetics of oral contraceptives in healthy women. Journal of clinical pharmacology 20050301
Nondaily hormonal contraception: establishing a fit between product characteristics and patient preferences. The Journal of family practice 20041101
[Hormonal contraceptive patch]. Ugeskrift for laeger 20041004
Induction of androgen receptor activity by norgestimate and norelgestromin in MDA-MB 231 breast cancer cells. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 20040701
An evaluation of the use of the transdermal contraceptive patch in adolescents. The Journal of adolescent health : official publication of the Society for Adolescent Medicine 20040501
New Product Review (September 2003). Norelgestromin/ethinyl oestradiol transdermal contraceptive system (Evra). The journal of family planning and reproductive health care 20040101
Matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 expression is not regulated by norgestimate or norelgestromin. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 20040101
Long-term evaluation of the use of the transdermal contraceptive patch in adolescents. TheScientificWorldJournal 20040101
[Transdermal contraception--a new beginning]. Akusherstvo i ginekologiia 20040101
New contraception options. Diabetes self-management 20040101
New hormonal contraceptives: a comprehensive review of the literature. Pharmacotherapy 20031201
Evra--a patch on oral contraception? Drug and therapeutics bulletin 20031201
[Medication of the month. Evra: first contraceptive transdermal patch]. Revue medicale de Liege 20031101
[A transdermal form of combined hormonal contraceptives (EVRA)]. Ceska gynekologie 20031001
Ortho Evra/Evra versus oral contraceptives: follicular development and ovulation in normal cycles and after an intentional dosing error. Fertility and sterility 20030701
New drugs 2003, part II. Nursing 20030701
Transdermal delivery of sex steroids for hormone replacement therapy and contraception. A review of principles and practice. The Journal of reproductive medicine 20030701
Ortho Evra, a new contraceptive patch. Pharmacotherapy 20030401
Transdermal contraceptive patch delivering norelgestromin and ethinyl estradiol. Effects on the lipid profile. The Journal of reproductive medicine 20030301
Serum distribution of the major metabolites of norgestimate in relation to its pharmacological properties. Contraception 20030201
Norelgestromin as selective estrogen enzyme modulator in human breast cancer cell lines. Effect on sulfatase activity in comparison to medroxyprogesterone acetate. The Journal of steroid biochemistry and molecular biology 20030201
Progress in contraception: new technology. International journal of fertility and women's medicine 20030101
Women prefer Ortho Evra patch. AWHONN lifelines 20030101
Transdermal ethinylestradiol/norelgestromin: a review of its use in hormonal contraception. Treatments in endocrinology 20030101
The introduction of a transdermal hormonal contraceptive (Ortho Evra/Evra). Fertility and sterility 20020201
Pharmacokinetic overview of Ortho Evra/Evra. Fertility and sterility 20020201
Contraceptive efficacy and cycle control with the Ortho Evra/Evra transdermal system: the analysis of pooled data. Fertility and sterility 20020201
A comparative and pooled analysis of the safety and tolerability of the contraceptive patch (Ortho Evra/Evra). Fertility and sterility 20020201
Assessment of compliance with a weekly contraceptive patch (Ortho Evra/Evra) among North American women. Fertility and sterility 20020201
Integrated summary of Ortho Evra/Evra contraceptive patch adhesion in varied climates and conditions. Fertility and sterility 20020201
Pharmacokinetics of a contraceptive patch (Evra/Ortho Evra) containing norelgestromin and ethinyloestradiol at four application sites. British journal of clinical pharmacology 20020201
Ortho Evra--a contraceptive patch. The Medical letter on drugs and therapeutics 20020121
The transdermal contraceptive patch: a new approach to hormonal contraception. International journal of fertility and women's medicine 20020101
Transdermal contraception. Seminars in reproductive medicine 20011201
Pharmacokinetics of norelgestromin and ethinyl estradiol delivered by a contraceptive patch (Ortho Evra/Evra) under conditions of heat, humidity, and exercise. Journal of clinical pharmacology 20011201
Pharmacokinetics of norelgestromin and ethinyl estradiol from two consecutive contraceptive patches. Journal of clinical pharmacology 20011101
Efficacy and safety of a transdermal contraceptive system. Obstetrics and gynecology 20011101
Multiple-dose pharmacokinetics of a contraceptive patch in healthy women participants. Contraception 20011101
Norgestimate. From the laboratory to three clinical indications. The Journal of reproductive medicine 20010701
Properties